Grants per year
Fingerprint
Dive into the research topics where Brendan Curti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
08/2/21 → 07/31/24
Project: Research
-
-
-
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
04/1/13 → 03/31/16
Project: Research
-
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers
Algazi, A. P., Moon, J., Lao, C. D., Chmielowski, B., Kendra, K. L., Lewis, K. D., Gonzalez, R., Kim, K., Godwin, J. E., Curti, B. D., Latkovic-Taber, M., Lomeli, S. H., Gufford, B. T., Scumpia, P. O., Lo, R. S., Othus, M. & Ribas, A., 2024, (Accepted/In press) In: Cancer.Research output: Contribution to journal › Article › peer-review
Open Access -
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
The CLEAR Trial Investigators, Apr 10 2024, In: Journal of Clinical Oncology. 42, 11, p. 1222-1228 7 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
PRESTO Study Investigators, Apr 1 2024, In: Journal of Clinical Oncology. 42, 10, p. 1114-1123 10 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
Silk, A. W., Curti, B., Bryan, J., Saunders, T., Shih, W., Kane, M. P., Hannon, P., Fountain, C., Felcher, J., Zloza, A., Kaufman, H. L., Mehnert, J. M. & McDermott, D. F., Feb 9 2023, In: Frontiers in Oncology. 13, 1108341.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.
Ann W, S., Curti, B., Bryan, J., Saunders, T., Shih, W., Michael P, K., Hannon, P., Christopher B, F., Felcher, J., Zloza, A., Howard L, K., Janice M, M. & David F, M., Jan 1 2023, In: Articles, Abstracts, and Reports.Research output: Contribution to journal › Article